|
US2020268659A1
|
|
Naloxone formulations for sublingual and/or buccal administration
|
|
US2016256415A1
|
|
Transmucosal ketamine delivery composition
|
|
AU2015292915A1
|
|
Solid dosage form composition for buccal or sublingual administration of cannabinoids
|
|
US2014303128A1
|
|
Transmucosal hormone delivery system
|
|
US2014303227A1
|
|
Transmucosal hormone delivery system
|
|
US2014274987A1
|
|
Transmucosal hormone delivery system
|
|
AU2014239651A1
|
|
Method of treating vitamin B12 deficiency
|
|
US2014303214A1
|
|
Transmucosal drug delivery system
|
|
US2014256765A1
|
|
Transmucosal drug delivery system
|
|
US2014256822A1
|
|
Transmucosal drug delivery system
|
|
US2014256823A1
|
|
Transmucosal drug delivery system
|
|
US2015080442A1
|
|
Transmucosal drug delivery system
|
|
US2014256766A1
|
|
Transmucosal drug delivery system
|
|
CN101677994A
|
|
Melatonin tablet and methods of preparation and use
|
|
AU2004216098A1
|
|
Transmucosal drug delivery system
|
